Interleukin Inhibitors Global Market Report 2024

The interleukin inhibitors market size has grown rapidly in recent years. It will grow from $42.93 billion in 2023 to $49.84 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. Historical growth was primarily driven by the increasing prevalence of autoimmune diseases, heightened awareness and adoption of interleukin inhibitors, a rising demand for personalized medicine, the expanding elderly population, and the growing acceptance of biosimilars.

The interleukin inhibitors market size is expected to see rapidly grown in the next few years. It will grow to $96.66 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%. Anticipated growth in the forecast period is linked to emerging therapeutic uses, the global increase in the aging population, combinations involving immunotherapy, and a rise in investment within research and development. Key trends expected in this period include the development of oral interleukin inhibitors, advancement in next-generation therapies, exploration of pediatric indications, expanded accessibility to treatments, and a strong focus on patient-centric care.

The burgeoning development of investigational drugs for inflammatory diseases like psoriasis, arthritis, and inflammatory bowel disease is set to propel the interleukin inhibitors market. These inhibitors curtail the actions of inflammatory cytokines, preserving tissue equilibrium and preventing harm to the host's immune responses. Presently, 48 molecules are under scrutiny for treating inflammatory conditions, with 20 in Phase III clinical trials. Upon approval, this robust pipeline is expected to drive the interleukin inhibitors market.

The escalating prevalence of bacterial infections stands as a driving force behind the interleukin inhibitors market. These inhibitors play a crucial role in combating bacterial diseases by hindering bacterial growth. In 2022, a cholera epidemic affected 30 countries, marking the highest case fatality ratio in a decade. Moreover, syphilis cases in the United States surged by 32% in 2021 compared to the previous year. This uptick in bacterial infections is a significant driver for the interleukin inhibitors market. The expiration of patents for biologic drugs creates pathways for biosimilars, presenting a more cost-effective alternative. Major players in the interleukin sector concentrate on biosimilar development for inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), pursued by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions. Despite the clinical advantages, limited patient access to biological therapy, primarily due to elevated treatment costs, drives the biosimilars trend. Rapid advancements in biotechnology and analytical sciences ensure biosimilar comparability to biological drugs, further bolstering this trend.

Leading market players are securing regulatory nods for novel antibiotic formulations. For instance, Risankizumab-rzaa, an FDA-approved interleukin-23 (IL-23) inhibitor, gained approval in June 2022 for treating adults with moderately to severely active Crohn's disease (CD). These drugs target specific cytokines and immune pathways, mitigating inflammation and enhancing patient outcomes, showcasing the market's commitment to innovative pharmaceuticals.

Major companies operating in the interleukin inhibitors market include Sanofi S.A., GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Seattle Genetics Inc., Genentech Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.

North America was the largest region in the interleukin inhibitors market in 2023. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of interleukin inhibitors encompass IL-17, IL-23, IL-1, IL-5, IL-6, among others. Interleukin 17, a pro-inflammatory cytokine from the cystine knot family, is produced by a specific subset of T helper cells called T helper 17 cells upon stimulation by IL-23. These inhibitors find application in treating conditions like psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and more. They are distributed through various channels, including hospital pharmacies, retail outlets, and online pharmacies.

The interleukin inhibitors market research report is one of a series of new reports provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.'

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.